Latest News and Press Releases

Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the...

Analyse der Phase-2a-Studie HOPE-KIDS 1 in oraler Präsentation vorgestellt Zwei Studien mit real world Daten zeigten nachhaltige Verbesserungen des Hämoglobins mit Oxbryta, im Einklang mit den...

L'analyse de l'étude de Phase 2a HOPE-KIDS 1 fait l'objet d'une présentation orale Deux études en vie réelle ont démontré des améliorations durables du taux d'hémoglobine avec Oxbryta, corroborant...

Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the...

SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2021, the compensation committee of GBT’s board of...

SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 42nd...

SOUTH SAN FRANCISCO, Kalifornien, May 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) kündigte heute an, dass auf dem Virtuellen Kongress der European Hematology...

SOUTH SAN FRANCISCO, Californie, 12 mai 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ : GBT) a annoncé aujourd'hui que six abstracts relatifs à son programme de...

SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that six abstracts related to its sickle cell disease (SCD) programs...

SOUTH SAN FRANCISCO, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2021, the compensation committee of GBT’s board of...